Cell Therapy in the US: Market Size, Businesses & Forecast 2026

The cell therapy industry in the United States comprises establishments dedicated to the research, clinical development, and manufacturing of cellular products designed to replace or repair damaged tissues and treat complex conditions like cancers and genetic disorders. As of 2026, the sector is experiencing significant expansion driven by an accelerating pipeline of chimeric antigen receptor (CAR) T-cell products and other advanced therapies cleared by federal regulators. The momentum of the market is underscored by critical operational metrics, such as the U.S. Food and Drug Administration (FDA) managing dozens of active approved cellular and gene therapy products and maintaining a small b

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Cell Therapy in the US industry cover?

The cell therapy industry involves the administration of live whole cells into a patient to treat or prevent a variety of human diseases. The scope encompasses both autologous therapies, which utilize a patient's own modified cells, and allogeneic therapies, which rely on cells from healthy donors. Activities cover the entire value chain including translational research, genetic engineering, clinical trials, and specialized bioprocessing.

• •Includes advanced therapeutic modalities such as CAR-T cell therapies, T-cell receptor (TCR) therapies, and stem cell transplants.
• •Covers contract development and manufacturing organizations (CDMOs) providing specialized cell processing facilities.
• •Excludes conventional blood transfusions and standard bone marrow transplants handled under routine medical practice.

Who operates in the industry and how is it structured?

The industry's market structure is highly integrated with the broader biopharmaceutical and medical research sectors. Operators vary from specialized clinical-stage biotechnology startups to global pharmaceutical conglomerates that acquire or partner with developers to leverage advanced manufacturing pipelines. Institutional academic medical centers also play a critical role as primary sites for early-stage trials and cell collection.

• •Primarily categorized under NAICS code 325414 for Biological Product Manufacturing and NAICS 541714 for Biotechnology Research and Development.
• •Relies heavily on specialized cold-chain logistics providers to manage cryopreserved cell transfers between hospitals and manufacturing sites.
• •The U.S. Small Business Administration applies a size standard of 1,000 employees in 2026 for research entities to qualify for federal small business programs.

What drives demand in the industry?

The expansion of cell therapy is primarily propelled by an increasing incidence of oncological and hematological malignancies that remain resistant to traditional chemotherapies. Furthermore, robust regulatory incentives designed to expedite pathways for serious medical conditions significantly pull therapies through development. The push for personalized medicine and curative, single-dose regimens rather than chronic disease management serves as a critical catalyst.

• •High demand exists for treating relapsed or refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma.
• •The FDA's Regenerative Medicine Advanced Therapy (RMAT) designation provides intensive guidance and expedited review for eligible products.
• •Expanding coverage and reimbursement determinations by the Centers for Medicare & Medicaid Services (CMS) broaden patient access to approved commercial therapies.

Who are the notable companies in the industry?

The competitive landscape features intense rivalry among multinational pharmaceutical corporations and pure-play biotechnology leaders racing to secure market share and expand indications. Competition is centered on therapeutic efficacy, manufacturing turnaround times, and the mitigation of severe side effects like cytokine release syndrome. Companies frequently utilize strategic licensing agreements and custom manufacturing networks to establish geographical advantages.

• •Bristol Myers Squibb Company operates as a major market participant with commercial CAR-T products including Breyanzi and Abecma.
• •Gilead Sciences, Inc., through its subsidiary Kite Pharma, is a dominant operator managing widely utilized cell therapies such as Yescarta and Tecartus.
• •Novartis AG maintains a foundational market position through Kymriah, the first FDA-approved CAR-T cell therapy.
• •Johnson & Johnson, in collaboration with Legend Biotech Corporation, actively markets Carvykti for the treatment of multiple myeloma.

What are the recent trends and outlook?

Recent trends are defined by a strategic shift from autologous cell production toward allogeneic, 'off-the-shelf' cell therapies to overcome high manufacturing costs and long preparation timelines. Automation of the cell-processing workflow is increasingly adopted to reduce human error and improve product consistency. The outlook remains strong as clinical trials expand into solid tumors and autoimmune indications like systemic lupus erythematosus.

• •Increased focus on decentralized 'point-of-care' manufacturing models inside major health networks to compress vein-to-vein timelines.
• •Rising incorporation of gene-editing technologies, such as CRISPR-Cas9, to enhance cellular durability and minimize graft-versus-host disease.
• •Expansion of manufacturing infrastructure across the U.S. to prevent product supply bottlenecks experienced during early commercial launches.

How is the industry regulated?

Cell therapies are stringently regulated by federal authorities due to their biological complexity and potential safety risks. Manufacturers must comply with comprehensive oversight governing product safety, purity, and potency before commercial distribution can occur. Facilities are subject to regular inspections to ensure that cellular manipulation adheres to precise quality standards.

• •Regulated by the FDA Center for Biologics Evaluation and Research (CBER) under Section 351 of the Public Health Service Act.
• •Operations must strictly follow Current Good Manufacturing Practice (cGMP) regulations for biological products.
• •Approved therapies are frequently mandated to operate under Risk Evaluation and Mitigation Strategies (REMS) to ensure safe clinical administration.

Government, statistical and trade sources used for this Claight analysis.

• U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research 2026 ·
• U.S. Small Business Administration (SBA) 2026 Size Standards ·
• Centers for Medicare & Medicaid Services (CMS) Reimbursement Files ·
• U.S. Census Bureau NAICS Definitions